The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes

References

• Acartürk F, Takka S. 1998. Calcium alginate microparticles for oral administration: II. Effect of formulation factors on drug release and drug entrapment efficiency. J Microencapsulation. 16:291–301.
   Web of Science ®Google Scholar
• Al-Kassas RS, Al-Gohary O, Al-Faadhel MM. 2007. Controlling of systemic absorption of gliclazide through incorporation into alginate beads. Int J Pharma. 341:230–237.
   PubMed Web of Science ®Google Scholar
• Al-Salami H, Butt G, Fawcett JP, Tucker IG, Golocorbin-Kon S, Mikov M. 2008a. Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats. Eur J Drug Metab Pharmacokinet. 33:101–106.
   PubMed Web of Science ®Google Scholar
• Al-Salami H, Butt G, Tucker I, Fawcett PJ, Golo-Corbin-Kon S, Mikov I, Mikov M. 2009. Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. Euro J Drug Metab Pharmacokinet. 34:43–50.
   PubMed Web of Science ®Google Scholar
• Al-Salami H, Butt G, Tucker I, Mikov M. 2008b. Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. Pharmacol Rep. 60:532–541.
   PubMed Web of Science ®Google Scholar
• Al-Salami H, Butt G, Tucker I, Mikov M. 2008c. Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. Methods Find Exp Clin Pharmacol. 30:107–113.
   PubMed Web of Science ®Google Scholar
• Al-Salami H, Butt G, Tucker I, Mikov M. 2008d. Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. Methods Find Exp Clin Pharmacol. 30:107–113.
   PubMed Web of Science ®Google Scholar
• Al-Salami H, Butt G, Tucker I, Skrbic R, Golocorbin-Kon S, Mikov M. 2008e. Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats. ArchDrug Inf. 1:35–41.
   Google Scholar
• Al-Salami H, Butt G, Tucker IG, Mikov M. 2008f. The Influence of Pre-Treatment with Probiotics on the in Vitro Ileal Permeation of the Antidiabetic Drug Gliclazide, in Healthy and Diabetic Rats. Drug Metabol Rev. 40:81–82.
   Web of Science ®Google Scholar
• Barakat NS, Almurshedi AS. 2011. Design and development of gliclazide‐loaded chitosan microparticles for oral sustained drug delivery: in‐vitro/in‐vivo evaluation. J Pharma Pharmacol. 63: 169–178.
   Web of Science ®Google Scholar
• Barakat NS, Shazly GA, Almedany AH. 2013. Influence of polymer blends on the characterization of gliclazide–encapsulated into poly (epsilon-caprolactone) microparticles. Drug Dev Ind Pharm. 39:352–362.
   PubMed Web of Science ®Google Scholar
• Berger J, Reist M, Mayer JM, Felt O, Gurny R. 2004. Structure and interactions in chitosan hydrogels formed by complexation or aggregation for biomedical applications. Eur J Pharma Biopharma. 57:35–52.
   PubMed Web of Science ®Google Scholar
• Biswal S, Sahoo J, Murthy P. 2009. Characterisation of gliclazide-PEG 8000 solid dispersions. Tropical J Pharma Res. 8:417–424.
   Web of Science ®Google Scholar
• Borges O, Borchard G, Verhoef JC, De Sousa A, Junginger HE. 2005. Preparation of coated nanoparticles for a new mucosal vaccine delivery system. Int J Pharma. 299:155–166.
   PubMed Web of Science ®Google Scholar
• Campbellt D, Laviellez R, Nathan CC. 1991The mode of action and clinical pharmacology of gliclazide: A review. Diab Res Clin Prac. 14:26–31.
   Web of Science ®Google Scholar
• Chan KLA, Elkhider N, Kazarian SG. 2005. Spectroscopic Imaging of Compacted Pharmaceutical Tablets. Chem Eng Res Des. 83: 1303–1310.
   Web of Science ®Google Scholar
• Chen X, Yang D, Shen W, Dong HF, Wang JM, Oppenheim JJ, Howard MZ. 2000. Characterization of chenodeoxycholic acid as an endogenous antagonist of the G-coupled formyl peptide receptors. Inflamm Res. 49:744–755.
   PubMed Web of Science ®Google Scholar
• Gill P, Moghadam TT, Ranjbar B. 2010. Differential scanning calorimetry techniques: applications in biology and nanoscience. J Biomol Tech. 21:167.
   PubMedGoogle Scholar
• Goyal N, Rana A, Bijjem K, Kumar P. 2015. Effect of chenodeoxycholic acid and sodium hydrogen sulfide in dinitro benzene sulfonic acid (DNBS) – Induced ulcerative colitis in rats. Pharmacol Rep. 67: 616–623.
   PubMed Web of Science ®Google Scholar
• Houten SM, Watanabe M, Auwerx J. 2006. Endocrine functions of bile acids. EMBO J. 25:1419–1425.
   PubMed Web of Science ®Google Scholar
• Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P. 2009. Bile acids as regulatory molecules. J Lipid Res. 50:1509–1520.
   PubMed Web of Science ®Google Scholar
• Kazarian SG, Chan KLA. 2006. Applications of ATR-FTIR spectroscopic imaging to biomedical samples. Biochim Biophys Acta Biomembranes. 1758:858–867.
   PubMed Web of Science ®Google Scholar
• Kazarian SG, Kong KWT, Bajomo M, Van Der Weerd J, Chan KLA. 2005. Spectroscopic Imaging Applied to Drug Release. Food Bioprod Process. 83:127–135.
   Web of Science ®Google Scholar
• Kuhajda K, Kandrac J, Kevresan S, Mikov M, Fawcett J. 2006. Structure and origin of bile acids: An overview. Eur J Drug Metab Pharmacokin. 31:135–143.
   PubMed Web of Science ®Google Scholar
• Mikov M, Al-Salami H, Golocorbin-Kon S, Skrbic R, Raskovic A, Fawcett JP. 2008. The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. Eur J Drug Metab Pharmacokin. 33:137–142.
   PubMed Web of Science ®Google Scholar
• Mikov M, Fawcett JP, Kuhajda K, Kevresan S. 2006. Pharmacology of bile acids and their derivatives: Absorption promoters and therapeutic agents. Eur J Drug Metab Pharmacokin. 31:237–251.
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Chen-Tan N, Al-Sallami HS, Fang Z, Mukkur T, et al. 2014a. Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol. Drug Des Devel Ther. 8:1221–1230.
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Chen-Tan N, Fakhoury M, Arfuso F, Jones F, Al-Salami H. 2014b. Advanced bile acid-based multi-compartmental microencapsulated pancreatic beta-cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment. Artif Cells Nanomed Biotechnol. 1–8.
   Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Chen-Tan N, Watts GF, Arfuso F, Al-Salami H. 2014c. An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer. Drug Des Devel Ther. 8:1673–1683.
   PubMed Web of Science ®Google Scholar
• Nayak BS, Ghosh SK, Patro KTB. 2009. Preparation and characterization of famotidine microcapsule employing mucoadhesive polymers in combination to enhance gastro retention for oral delivery. Int J Pharm Sci. 1:112–120.
   Google Scholar
• Nayak AK, Hasnain MS, Beg S, Alam MI. 2010. Mucoadhesive beads of gliclazide: Design, development, and evaluation. Science Asia. 36:319–325.
   Web of Science ®Google Scholar
• Negrulj R, Mooranian A, Chen-Tan N, Al-Sallami HS, Mikov M, Golocorbin-Kon S, et al. 2015. Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes. Artif Cells Nanomed Biotechnol. 1–8.
   PubMed Web of Science ®Google Scholar
• Prajapati S, Tripathi P, Ubaidulla U, Anand V. 2008. Design and development of gliclazide mucoadhesive microcapsules: in vitro and in vivo evaluation. AAPS PharmSciTech. 9:224–230.
   PubMed Web of Science ®Google Scholar
• Prajapati VD, Mashru KH, Solanki HK, Jani GK. 2013. Development of modified release gliclazide biological macromolecules using natural biodegradable polymers. Int J Biol Macromol. 55:6–14.
   PubMed Web of Science ®Google Scholar
• Ribeiro AJ, Silva C, Ferreira D, Veiga F. 2005. Chitosan-reinforced alginate microspheres obtained through the emulsification/internal gelation technique. Eur J Pharma Sci. 25:31–40.
   PubMed Web of Science ®Google Scholar
• Rokstad AM, Lacík I, De Vos P, Strand BL. 2014. Advances in biocompatibility and physico-chemical characterization of microspheres for cell encapsulation. Adv Drug Deliv Rev. 67–68:111–130.
   PubMed Web of Science ®Google Scholar
• Sarmento B, Ferreira D, Veiga F, Ribeiro A. 2006. Characterization of insulin-loaded alginate nanoparticles produced by ionotropic pre-gelation through DSC and FTIR studies. Carbohydr Polym. 66:1–7.
   Web of Science ®Google Scholar
• Sartori C, Finch DS, Ralph B, Gilding K. 1997. Determination of the cation content of alginate thin films by FTi.r. spectroscopy. Polymer. 38:43–51.
   Web of Science ®Google Scholar
• Takka S, Cali AG. 2012. Bile salt-reinforced alginate-chitosan beads. Pharm Dev Technol. 17:23–29.
   PubMed Web of Science ®Google Scholar
• Tormo MA, Zubeldia MA, Montero JL, Campillo JE. 1989. Gliclazide increases glucose utilization by rat intestine in vitro. Diabete Metab. 15:170–175.
   PubMed Web of Science ®Google Scholar
• Tsutsumi K, Li SK, Hymas RV, Teng CL, Tillman LG, Hardee GE, et al. 2008. Systematic studies on the paracellular permeation of model permeants and oligonucleotides in the rat small intestine with chenodeoxycholate as enhancer. J Pharm Sci. 97:350–367.
   PubMed Web of Science ®Google Scholar
• Wang YJ. 2000. Development of new polycations for cell encapsulation with alginate. Mater Sci Eng C. 13:59–63.
   Web of Science ®Google Scholar
• Wong TW, Chan LW, Kho SB, Sia Heng PW. 2002. Design of controlled-release solid dosage forms of alginate and chitosan using microwave. J Control Release. 84:99–114.
   PubMed Web of Science ®Google Scholar
• Yang L, Fawcett JP, Ostergaard J, Zhang H, Tucker IG. 2012. Mechanistic studies of the effect of bile salts on rhodamine 123 uptake into RBE4 cells. Mol Pharm. 9:29–36.
   PubMed Web of Science ®Google Scholar
• Yasukawa K, Iida T, Fujimoto Y. 2009. Relative inhibitory activity of bile acids against 12-O-tetradecanoylphorbol-13-acetate-induced inflammation, and chenodeoxycholic acid inhibition of tumour promotion in mouse skin two-stage carcinogenesis. J Pharm Pharmacol. 61:1051–1056.
   PubMed Web of Science ®Google Scholar